Moderna stock price prediction: Range-bound trading expected

Traders Union
All News
Stocks
Moderna slides 2.23% to $145.55 today

Highlights

Moderna and Merck reported positive Phase III results for the AI-designed mRNA-4157 melanoma immunotherapy with pembrolizumab.
This is the first mRNA immunotherapy to complete a Phase III trial, increasing the likelihood of future regulatory approval and oncology revenue.
Moderna stock trades in a short-term range of $135.89 to $155.21 with mixed technical signals and a 59% probability of upward movement.

First mRNA cancer trial success boosts outlook amid selling pressure

Moderna and Merck reported positive Phase III clinical trial results for an AI-designed, patient-specific mRNA-4157 (V940) immunotherapy in combination with pembrolizumab for melanoma, according to Bioxconomy. This outcome marks the first mRNA immunotherapy to successfully complete a Phase III trial and positions the candidate as a potential frontrunner for bespoke cancer immunotherapy regulatory approval. The clinical advance enhances Moderna’s long-term prospects by increasing the probability of future market access and revenue in oncology, though price action has remained under broader selling pressure.

Resistance and oscillators reflect mixed momentum in volatile trade

MRNA is currently situated below its MA-20 at $146.51, but above the MA-50 at $144.18 and well above the MA-200 at $54.83. The Ichimoku Kijun sits at $148.98 and acts as immediate resistance, with the session opening in a 4.65 point gap to the downside. Momentum signals present a mixed picture: RSI is at 49.59 and signals Sell, while MACD, ADX, Stochastic RSI, CCI, and the Awesome Oscillator each remain neutral. Bull/Bear Power continues to flag overbought conditions, indicating recent buyer dominance within the intraday action. Price has gravitated toward the session’s low on high volatility, with oscillator-trend divergences highlighting a complex and indecisive intraday tone.

Sideways trend likely as volatility drives range-bound scenarios

In the short term, MRNA is expected to consolidate in a $135.89 to $155.21 range, reflecting recent volatility bands relative to current levels. The baseline scenario is for sideways movement within these bounds. A bullish outcome could see the price overcoming resistance at the Ichimoku Kijun, enabling a move toward the upper range boundary, while a bearish scenario would involve a break below support and a potential test of the lower end of the band. Short-term probability models assign a 59% chance to an upward move and a 41% chance to a decline.

Viktoras Karapetjanc, senior analyst at Traders Union, sees the recent clinical milestone as a pivotal moment for Moderna’s long-term value. He believes the first successful Phase III results for mRNA-4157 highlight strong fundamental momentum, even as the stock faces short-term volatility. Despite sideways price movement, the case for future growth in oncology remains intact. "With regulatory progress and robust science on Moderna’s side, I see constructive upside potential for the stock as long as broader sentiment stabilizes."

Earlier, analysts noted that while sector strength was supportive, Moderna stock faced significant short-term risks due to technical overheating. The current article adds a new dimension with the positive Phase III trial update but highlights ongoing volatility and mixed momentum signals, making the $135.89 to $155.21 consolidation range an important focus for near-term positioning.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.